BLOG / 🇺🇸 United States · · daily

Mega Contracts Monitor ($100M+) — August 01, 2026

Mega Contracts Monitor ($100M+)

By Gunpowder Editorial ·

2 total filings analysed

Executive Summary

The two contracts analyzed total $956.9 million in obligations, with one defense-related award (AT&T to State Department) and one civilian award (Regeneron to HHS). The dominant theme is civilian biodefense R&D, driven by Regeneron's $695.7 million cost-plus-fixed-fee contract from BARDA, which provides stable, long-term revenue visibility through 2027.

The highest-conviction signal is bullish for Regeneron, given the low pricing risk and competitive win, though the vague program description introduces execution uncertainty. The AT&T contract is a completed award with no ongoing revenue, offering limited forward-looking insight. Key risk: the Regeneron contract's 10-year duration and lack of specific deliverables could lead to underperformance or scope changes.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior Mega Contracts Monitor ($100M+) digest from July 31, 2026.

Investment Signals (2)

  • Regeneron Pharmaceuticals Secures $695.7M BARDA Contract for Biodefense R&D (HIGH)

    Regeneron won a $695.7 million cost-plus-fixed-fee contract from BARDA (HHS) under full-and-open competition, providing low-risk revenue with cost recovery and a 10-year performance period through 2027.

  • AT&T Completes $261.1M State Department Telecom Contract, No Ongoing Revenue (LOW)

    AT&T's $261.1 million firm-fixed-price delivery order for telephone systems at foreign posts ended in March 2021, with only $27.3 million outlaid, indicating a completed award with no current revenue contribution.

Risk Flags (2)

  • Execution [MEDIUM RISK]

    Regeneron's $695.7M BARDA contract has a vague program description ('IGF::OT::IGF'), limiting visibility into specific deliverables and increasing execution uncertainty over the 10-year period.

  • Concentration [LOW RISK]

    The digest contains only two contracts, with one (AT&T) being a completed award, resulting in a narrow data set that limits cross-contract pattern analysis.

Opportunities (2)

  • Regeneron's $695.7M BARDA contract signals sustained government investment in biodefense and pandemic preparedness, creating growth opportunities for biotechnology firms with R&D capabilities in medical countermeasures.

  • The Department of State's $261.1M telecom contract, though completed, indicates ongoing investment in diplomatic communications infrastructure, suggesting potential follow-on contracts for telecommunications providers.

Sector Themes (2)

  • Regeneron's $695.7M BARDA contract underscores sustained federal funding for biotechnology R&D in pandemic preparedness and biodefense, with a cost-plus structure that reduces contractor risk.

  • AT&T's completed $261.1M State Department telecom contract provides no ongoing revenue, highlighting that older awards may not reflect current competitive positioning or growth prospects.

Watch List (2)

  • 👁

    {"entity" => "Regeneron Pharmaceuticals", "reason" => "The $695.7M BARDA contract provides long-term revenue visibility, but execution uncertainty and vague program details warrant monitoring.", "trigger" => "Future outlay amounts, option exercises, or modifications to the contract"}

  • 👁

    {"entity" => "AT&T Technical Services Company", "reason" => "The completed $261.1M State Department contract may be followed by a re-compete for telecommunications services at foreign posts.", "trigger" => "Re-compete announcement from the Department of State"}

Get daily alerts with 2 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 2 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: Mega Contracts Monitor ($100M+)

🇺🇸 More from United States

View all →